---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-22-000030"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T00:40:24.737415+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q3 revenue up 24% YoY to $505M; VOXZOGO guidance raised to $140-170M

## Summary
- Total revenues $505.3M (+24% YoY); GAAP net loss narrowed to $6.7M from $36.5M; Non-GAAP income $82.7M.
- VOXZOGO net product revenue $48.3M, with 713 children treated; full-year guidance raised to $140-170M.
- ROCTAVIAN BLA accepted by FDA, PDUFA March 31, 2023; EU commercial launch underway after August 2022 approval.
- KUVAN revenue fell 16% QoQ and 20% YTD due to U.S. generic competition, as expected.
- Full-year total revenue guidance reaffirmed at $2.06-2.16B; R&D and SG&A guidance ranges revised modestly.

## SEC filing metadata
- accession: 0001048477-22-000030
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/0001048477-22-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847722000030/bmrn-20221026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-22-000030
- JSON: https://secwatch.observer/filing/0001048477-22-000030.json
- Plain text: https://secwatch.observer/filing/0001048477-22-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.